Wedmont Private Capital Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wedmont Private Capital bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,881 shares of the specialty pharmaceutical company’s stock, valued at approximately $214,000.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after purchasing an additional 29,960 shares in the last quarter. FMR LLC boosted its stake in shares of Jazz Pharmaceuticals by 8.1% during the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares during the last quarter. Ameriprise Financial Inc. increased its position in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock worth $168,222,000 after purchasing an additional 57,717 shares in the last quarter. Polaris Capital Management LLC raised its stake in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after purchasing an additional 27,100 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 28.1% during the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after acquiring an additional 224,865 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Truist Financial restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Needham & Company LLC lowered their target price on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $190.00.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $107.97 on Monday. The firm has a market capitalization of $6.81 billion, a PE ratio of 22.26, a P/E/G ratio of 1.65 and a beta of 0.62. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70. The company’s 50 day simple moving average is $109.08 and its 200 day simple moving average is $117.16.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The firm had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.